| Literature DB >> 29182623 |
Urai Chaisri1, Anchalee Tungtrongchitr2,3, Nitaya Indrawattana4, Panisara Meechan3, Watchara Phurttikul3, Natt Tasaniyananda3, Nawannaporn Saelim2,3, Wanpen Chaicumpa2,3, Nitat Sookrung3,5.
Abstract
Allergen specific immunotherapy (AIT) can modulate the allergic response causing a long-term symptom subsidence/abolishment which leads to reduced drug use and prevention of new sensitization. AIT of house dust mite allergy (HDM) using the mite crude extract (CE) as the therapeutic agent is not only less effective than the AIT for many other allergens, but also frequently causes adverse effects during the treatment course. In this study, mouse model of Dermatophagoides pteronyssinus (Dp) allergy was invented for testing therapeutic efficacies of intranasally administered liposome (L) encapsulated vaccines made of single Dp major allergens (L-Der p 1, L-Der p 2), combined allergens (L-Der p 1 and Der p 2), and crude Dp extract (L-CE). The allergen sparing intranasal route was chosen as it is known that the effective cells induced at the nasal-associated lymphoid tissue can exert their activities at the lower respiratory tissue due to the common mucosal traffic. Liposome was chosen as the vaccine delivery vehicle and adjuvant as the micelles could reduce toxicity of the entrapped cargo. The Dp-CE allergic mice received eight doses of individual vaccines/placebo on alternate days. All vaccine formulations caused reduction of the Th2 response of the Dp allergic mice. However, only the vaccines made of single refined allergens induced expressions of immunosuppressive cytokines (TGF-β, IL-35 and/or IL-10) which are the imperative signatures of successful AIT. The data emphasize the superior therapeutic efficacy of single refined major allergen vaccines than the crude allergenic extract vaccine.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29182623 PMCID: PMC5705073 DOI: 10.1371/journal.pone.0188627
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Indirect ELISA OD405nm (means ± SD) of Dp-CE-specific IgE in sera of allergenized mice compared to sham and normal mice (A) before receiving vaccines/placebo (BV). (B) PP, Dp-CE-specific IgE in sera of allergic mice after treatment with vaccines (L-CE, L-Der p 1, L-Der p 2, and L-Com) and provoked with aerosolic Dp-CE compared with placebo (L-PBS) and sham mice. Bars with different superscripts of BV or PP were different at p ≤ 0.05.
Fig 2Indirect ELISA OD405nm (means ± SD) of Dp-CE-specific IgG1 in sera of allergenized mice compared to sham and normal mice (A) before receiving vaccines/placebo (BV) and (B) Dp-CE-specific IgG1 in sera of allergic mice after treatment with the vaccines and provoked with aerosolic Dp-CE compared with placebo and sham mice (PP).
Bars with different superscripts of BV or PP were different at p ≤ 0.05.
Inflammatory cells in lungs of Dp-CE allergic mice compared with normal and sham mice before vaccination (BV) and after vaccination/placebo and provocation with Dp-CE (PP).
| Group | Mean ± SD of cells/microscopic field | ||||
|---|---|---|---|---|---|
| Neutrophil | Lymphocyte | Eosinophil | Macrophage | Total cells | |
| Normal | 4.46 ± 3.32 a | 3.05 ± 6.57a | 0 | 0.188 ± 1.68a | 7.70 ± 7.47a |
| Sham | 37.28 ± 25.83b | 9.275 ± 5.70b | 0 | 0 | 46.55 ± 26.27b |
| Allergenized mice | 88.66 ± 43.47 c | 125.44 ± 71.89c | 1.15 ± 2.27 a | 0 | 215.25 ± 90.85c |
| Sham | 31.76 ± 22.90b | 11.41 ± 14.01b | 0 | 0 | 43.18 ± 35.02b |
| L-CE | 119.33 ± 56.17c | 61.44 ± 64.87d | 0.96 ± 1.69a | 0.10 ± 0.27a | 181.84 ± 89.86d |
| L- Der p 1 | 48.73 ± 36.99d | 37.79 ± 37.75e | 0.24 ± 0.75b | 0.05 ± 0.30a | 86.81 ± 64.31e |
| L-Der p 2 | 55.42 ± 12.70e | 36.36 ± 8.47e | 0.45 ± 0.81c | 0 | 92.23 ± 24.47e |
| L-Com | 46.31 ± 26.35d | 35.76 ± 34.16e | 0.25 ± 0.91b | 0.05 ± 0.29a | 82.37 ± 47.74e |
| L-PBS | 68.54 ± 44.31c,e | 41.91 ± 53.89e | 0.20 ± 1.02b | 0.04 ± 0.28a | 110.69 ± 87.30f |
*, Average of at least 20 microscopic fields (10 × 40) per mouse
Entries with different superscripts (a, b, c, d, e and f) of the same column are statistically different (p <0.05)
Fig 3Histopathological grades (mean ± SD) of lung tissues of (A) allergenized, sham and normal mice (BV) and (B) allergenized mice that received vaccines/placebo followed by provocation (PP).
Bars with different letters (a and b in A) and (a, b, c, and d in B) are statistically different at p ≤ 0.05.
Fig 4Cytokine expression profiles of normal, sham and allergenized mice.
Characteristics of L-CE, L-Der p 1, L- Der p 2, and L-Com vaccines and placebo (L-PBS).
| Parameter | Vaccine formulation | Placebo | |||
|---|---|---|---|---|---|
| L-CE | L-nDer p 1 | L- nDer p 2 | L-Com | ||
| Average size (μm) | 4.566 ± 0.023a | 1.999 ± 0.034b | 2.016 ± 0.120b | 1.025 ± 0.002c | 1.93 ± 0.02b |
| Polydispersity | 0.311 ± 0.078a | 0.799 ± 0.071b | 0.788 ± 0.070 b | 0.536 ± 0.020c | 1.00 ± 0.00d |
| Zeta potential | 31.33±0.58a | 35.40 ± 0.794a | 33.60 ± 1.058a | 35.00 ± 0.00a | 34.3 ± 2.15a |
| % Entrapment | 81.64 | 88.03 | 90.56 | 88.34 | NA |
NA, not applicable
Entries with different superscripts (a, b, c and d) of the same horizontal line are statistically different (p <0.05)
Percent entrapment was calculated from one aliquot of each vaccine
Fig 5Cytokine expression profiles of Dermatophagoides pteronyssinus allergic mice after treatment with liposome-encapsulated vaccines/placebo and allergen provocation.